Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Ticker
CMMB
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$11.15M
52-week range
$0.92 - $2.99
Valuation
Share price
$1.55 (close of Nov 18, 2026)
P/E (TTM)
-1.08x
Price to book
0.90x
Price to free cash flow
-1.00x
Enterprise value
$748.01K
Book value per share
$1.71
Price performance
Period
Change
1 day
-5.49%
5 days
+14.81%
1 month
+23.02%
3 months
-18.85%
6 months
-4.32%
Year to date
-6.06%
1 year
-43.22%
3 years
-32.02%
5 years
-95.73%
All time
-99.78%
Short interest
As of
Oct 30, 2026
Short % of float
0.07%
Shares short
5.14K
Days to cover
0.11
Change since prior report
-63.00%
Source
FINRA consolidated short interest
Profitability and growth
Return on equity
-72.93%
Return on assets
-65.12%
Cash flow and balance sheet
Free cash flow yield (TTM)
-99.87%
Current ratio
9.08x
Net debt to EBITDA
1.10x
Latest reported year
Period end
Dec 31, 2025
Fiscal year
2025
EBITDA
-$111.93M
Net income
-$8.99M
Earnings per share
$-1.44
Research and development
$5.83M
Shares outstanding
6.38M
Income statement by year
Period end
Net income
EPS
2025-12-31
-$8.99M
-$1.44
2024-12-31
-$13.95M
-$3.12
2023-12-31
-$24.22M
-$8.24
2022-12-31
-$27.65M
-$9.68
2021-12-31
-$12.48M
-$4.80
2020-12-31
-$5.95M
$3.52
2019-12-31
-$27.12M
$1,011.20
2018-12-31
-$13.80M
$1,395.20
2017-12-31
-$9.81M
-$1.70
2016-12-31
-$4.74M
-$1.24
Margins and returns by year
Period end
Return on equity
Return on capital
2025-12-31
-72.93%
-
2024-12-31
-103.01%
-
2023-12-31
-142.50%
-139.29%*
2022-12-31
-76.32%
-75.87%*
2021-12-31
-20.30%
-20.19%*
2020-12-31
-55.09%
53.05%*
2019-12-31
-219.22%
201.15%*
2018-12-31
-140.72%
-113.12%
2016-12-31
-144.01%
-
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.